Target intelligence / Profile preview

Major cat allergen 1 (Fel d 1) (Fel d 1)

Target
Fel d 1
Molecular classification
Secretoglobin, Glycoprotein, Other
01

Overview

Major cat allergen 1, widely known as Fel d 1, is a secretoglobin protein produced primarily in the sebaceous and salivary glands of the domestic cat (Felis catus). It exists as a 35-38 kDa heterotetrameric glycoprotein composed of two identical heterodimers, each containing two polypeptide chains linked by disulfide bonds. While its precise biological function in felines is not fully understood, it is hypothesized to serve as a carrier for pheromones or other lipid ligands, or to provide protective functions for the skin and mucosa. In humans, Fel d 1 is the most potent feline allergen, responsible for inducing immunoglobulin E (IgE)-mediated allergic responses in over 90% of cat-allergic individuals. Due to its small aerodynamic size and high environmental stability, Fel d 1 remains airborne for long periods and persists on surfaces, triggering symptoms ranging from allergic rhinitis and conjunctivitis to severe asthmatic exacerbations. Therapeutic interventions include monoclonal antibodies like the REGN1908/1909 cocktail, which neutralize the allergen to prevent mast cell degranulation, as well as cat-targeted vaccines and dietary interventions designed to reduce the allergen load at the source.

Other names
Fel d 1Felis domesticus allergen 1Fel d ISecretoglobin family 1A member 2 (Chain 1)Secretoglobin family 2A member 1 (Chain 2)
02

Mechanism of action

Neutralization of the allergen to prevent binding to IgE on mast cells and basophils; Induction of immunological tolerance through peptide or allergen-specific immunotherapy; Reduction of allergen production in the host (feline) via vaccination or dietary antibodies.

03

Biological functions

Pheromone bindingLipid molecule transportImmune modulationEpithelial protectionChemical signaling
04

Disease associations

Allergic rhinitisAllergic conjunctivitisAllergic asthmaAtopic dermatitisInflammation
05

Safety considerations

Risk of systemic allergic reactions or anaphylaxis during immunotherapyRisk of acute asthma exacerbation during environmental exposure challengesPotential theoretical cross-reactivity with human secretoglobins like human uteroglobinTherapeutic challenge of high environmental persistence and widespread distribution of the allergen
06

Interacting drugs

REGN1908

5 more in the full profile.

07

Biomarkers

Fel d 1-specific IgE levelsSkin prick test (SPT) reactivityForced expiratory volume in 1 second (FEV1)Fractional exhaled nitric oxide (FeNO)Total Nasal Symptom Score (TNSS)

Beyond the preview

Go deeper on Major cat allergen 1 (Fel d 1) (Fel d 1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Major cat allergen 1 (Fel d 1) (Fel d 1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call